Should be Tuesday as Monday is Labour day in the USA. The problem could be that there is only one long lasting ER LIQUID RX drug on the market Tussionex,most of the 2 billion spent on cold RX drugs are short lasting ones,the good news is Tussionex was developed by Tris Pharm. in partnership with Par Pharm.,sales for the Drug are around 221 million dollars. Its certainly not a given but Tris are experts in developing Liquid RX drugs. Also there will be milestone payments to Tris on FDA approval and big set up costs in the USA at the moment Vernalis employ 2 full time sales people in the US both have worked on the Tussionex drug but this will increase to 80 - 100 sales persons on approval up to 200 if they manage to get the other 4 through,should be upside in the share price but may be limited due to the unknown sales of the drug and R&D spend if given approval.
Tuzistra FDA Approval
I understand that Tuzistra was submitted for FDA approval on 30 June 2014. The FDA should then conduct a substantive review within 60 days. So does anyone know when VER is expecting a decision to be made? I’m guessing this should be at the end of August. However, it is rare that approval is granted first time and I fully expect VER to have to submit further information which will drag the approval into 2015. If VER does get FDA approval expect big hikes in the SP.
20 Aug '14
Just think if you could do that every 2 or 4 weeks. I'd be happy with that!
20 Aug '14
Profit is profit. But if you have some spare funds a re-investment in VER (at the current price) wouldn't be a bad bet. Can see this one increasing by 33%+.
20 Aug '14
Did not really want to yet, but made about 25% profit in 12 days and wanting to rebuy another share. GLA
19 Aug '14
RE: Price Target
54p sounds like a good target. I'd expect a spike higher than that though. Gla
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.